The US Food and Drug Administration (FDA) has granted approval for Intelence, a treatment specifically indicated for treatment-experienced patients who have experienced virologic failure from antiviral-resistant HIV-1 strains.
The FDA has recommended Intelence, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to an NNRTI and other antiretroviral (ARV) agents.
Go deeper with GlobalData
Approval for the treatment, currently marketed in the US by Tibotec Therapeutics, was based on successful 48-week data from two Phase 3 studies known as DUET-1 and DUET-2.
In each study, more patients achieved a significantly undetectable viral load with Intelence tablets plus a background regimen compared with a placebo plus a background regimen.
DUET clinical investigator Charles Hicks said that Intelence (etravirine) has become an important option for many treatment-experienced patients with resistance to NNRTIs or other antiretrovirals.
Intelence received accelerated approval from the FDA in January 2008 and has since been approved in more than 50 countries. This additional indication was submitted to the FDA in January 2009.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
